Can Low-Dose CT Screening Slash Lung Cancer Mortality?
Recent evidence confirms that low-dose CT screening significantly reduces lung cancer deaths among high-risk individuals. An international expert panel convened by the International Agency for Research on Cancer published these landmark findings in The New England Journal of Medicine. Notably, Dr Abhishek Shankar from the All India Institute of Medical Sciences contributed directly to this global review. Consequently, clinicians now possess stronger guidance to target high-risk patients who benefit from early detection protocols.
Trial Evidence Supporting Low-Dose CT Screening
Specifically, large randomized clinical trials provide robust evidence for this intervention. In the landmark US National Lung Screening Trial, low-dose CT reduced lung cancer mortality by 16% compared to chest radiography. Furthermore, the European NELSON trial confirmed substantial mortality reductions among screened participants at ten years.
Because of this consistent data, the expert panel assigned a Group A classification to this imaging modality. This designation signals unequivocal efficacy in reducing both lung cancer deaths and late-stage diagnoses. In contrast, researchers classified conventional chest radiographs as Group C. Therefore, clinicians should not use plain radiographs for routine screening.
High-Risk Criteria and the Indian Lung Screening Trial
Clearly, screening delivers the greatest value when clinicians target strictly defined risk profiles. Eligible groups typically include individuals aged 50 to 80 years with at least 20 pack-years of smoking. In addition, eligible candidates include former smokers who quit within the preceding 15 years.
In India, Dr Abhishek Shankar currently leads the Indian Lung Screening Trial at AIIMS New Delhi. Thus, eligible individuals with heavy tobacco exposure can enroll for organized screening under this initiative. However, effective programs require comprehensive systems for nodule management and smoking cessation support.
Managing False Positives and Overdiagnosis
Nevertheless, physicians must remain mindful of the potential clinical harms of screening. False-positive rates vary widely across published trials, ranging from 1% to 42% depending on nodule evaluation protocols. Consequently, between 5% and 32% of patients with false-positive results undergo invasive downstream procedures. Moreover, procedural complications occur in 10% to 22% of these invasive interventions.
Additionally, researchers estimate that 3% to 26% of screen-detected lesions represent overdiagnosis. These indolent tumors might never cause clinical symptoms during the individual's natural lifetime. Therefore, clinicians must engage patients in shared decision-making before initiating scans.
Frequently Asked Questions
Q1: Who is eligible for low-dose CT lung cancer screening?
Screening is recommended for adults aged 50 to 80 years who have a smoking history of at least 20 to 30 pack-years. Furthermore, former smokers who quit within the past 15 years remain eligible candidates.
Q2: Why are conventional chest X-rays not recommended for screening?
Randomized trials demonstrate that chest X-rays fail to reduce lung cancer mortality. Consequently, international bodies classify chest radiography as Group C, confirming no proven screening benefit.
Q3: How can eligible patients in India join the Indian Lung Screening Trial?
Eligible individuals aged 50 to 80 with significant smoking history can contact the trial team led by Dr Abhishek Shankar at AIIMS New Delhi for evaluation and structured screening.
References
- Lung cancer deaths down 16% with low-dose CT screening: IARC - ETHealthworld
- Neamtiu L, Callister MEJ, Crosbie P, et al. IARC Perspective on Lung Cancer Screening. New England Journal of Medicine. 2026.
- National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine. 2011;365(5):395-409.
